Hematology

Latest News

FDA approved. | Image Credit: Pawel - stock.adobe.com

Treosulfan Regimen Approved for Allo-HSCT Conditioning in AML/MDS

By Rose McNulty

January 23rd 2025

The FDA approved treosulfan in combination with fludarabine as preparation for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adult and pediatric patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Infection risk concept; floating bacterial particles | image credit: ChaoticMind - stock.adobe.com

High Infection Risk in MM: Insights From the Pre-Immunotherapy Era

January 21st 2025

First-line treatment for MDS often includes hypomethylating agents, so it is common for patients with sAML to have prior exposure to these agents. - Eleni - stock.adobe.com

Unmet Needs Remain in Secondary AML Following Treatment With HMAs

By Rose McNulty

January 18th 2025

Man donating blood | Image Credit: © New Africa - stock.adobe.com

5 Medications That Defer Blood Donation

By Maggie L. Shaw

January 17th 2025

MRD status cannot be detected with a microscope and is achieved through bone marrow analysis | image credit: Arthur Constantine - stock.adobe.com

MRD Negativity: A "Robust" Predictor of Survival Outcomes in MM

January 13th 2025

More News

October 17th 2017

Looking Ahead at the Specialty Drug Pipeline After an Active Year of Approvals

Christina Mattina

Aimee Tharaldson, PharmD, of Express Scripts kicked off the Academy of Managed Care Pharmacy (AMCP) 2017 Nexus, held October 16-19 in Dallas, Texas, with a presentation on the pipeline of specialty pharmaceuticals in development.

October 16th 2017

St. Jude Study Questions Efficacy of the Flu Vaccine in Children With Leukemia

Surabhi Dangi-Garimella, PhD

The study found that young patients with leukemia who have been vaccinated against the influenza virus are as susceptible to develop flu as their unvaccinated peers.

October 16th 2017

Pharmacy Team Engagement in Navigating the Revenue Cycle for High-Cost Medications in Patients With Cancer

Brandon R. Shank, PharmD, MPH, BCOP Phuoc Anh (Anne) Nguyen, PharmD, MS, BCPS Emily C. Pherson, PharmD, BCPS

With the clinical and financial implications of high-cost medications, and their impact on health system revenue, it is of utmost importance for all key stakeholders to be engaged in the complex revenue cycle.

October 13th 2017

Study: Body Fat Composition May Predict Poor Treatment Outcomes in Patients With Multiple Myeloma

A recent study found that excess body fat in the abdomen and pelvis may predict poor treatment response in patients with multiple myeloma.

October 13th 2017

In Conversation With a Pharmacist: Management of CAR T-Cell Treatment

Surabhi Dangi-Garimella, PhD

Evidence-Based OncologyTM sat down with Brandon R. Shank, PharmD, MPH, BCOP, clinical pharmacy specialist, Division of Pharmacy, The University of Texas MD Anderson Cancer Center, to understand a pharmacist's role in administering chimeric antigen receptor (CAR) T cells.

October 12th 2017

Second Interim Analysis Suggests Carfilzomib Improves Survival in Multiple Myeloma

Alison Rodriguez

Following the phase 3 ENDEAVOR trial that compared 2 proteasome inhibitors-carfilzomib and bortezomib-in relapsed or refractory multiple myeloma patients, researchers conducted a second interim analysis to compare the overall survival between the 2 groups.

October 10th 2017

Study Finds Antibiotic Effective in Reducing Rate of Infection in Children With ALL

Alison Rodriguez

October 7th 2017

LLS Survey Shows Lack of Blood Cancer Awareness in the United States

Alison Rodriguez

A recent survey by The Leukemia & Lymphoma Society found that the majority of adults are surprised by the prevalence of blood cancers-specifically the prevalence of acute lymphocytic leukemia among children and young adults.

October 6th 2017

Report Analyzes Pipeline of Drugs for Treating Chemotherapy-Related Toxicities

Alison Rodriguez

A recent report, “Toxicology Cluster Chemotherapy Related Toxicity Drug Development Pipeline Review, 2017,” presents a summary of drugs in development to treat chemotherapy-related toxicities.

September 18th 2017

New CDC Report Provides Update on Incidence Rates of Pediatric ALL

Surabhi Dangi-Garimella, PhD

New results published in CDC’s Morbidity and Mortality Weekly Report have identified a surge in pediatric acute lymphoblastic leukemia (ALL) during the period 2001 to 2008, followed by stabilization during 2008 to 2014.

September 15th 2017

Copanlisib Receives Accelerated Approval for Relapsed Follicular Lymphoma

Christina Mattina

Patients with relapsed follicular lymphoma now have a new treatment option: copanlisib, a kinase inhibitor that was recently approved through the FDA’s accelerated approval process.

September 4th 2017

Healthy, but Still Hurting: Challenges of Cancer Survivorship

Laura Joszt, MA

The assumption in the United States is that once someone with cancer is cured, done with treatment, and healthy, that they are now okay. However, the reality is that survivors contend with lingering challenges that aren’t visible and make it difficult for them to ask for help or admit they need it.

September 1st 2017

A New Treatment Option for Newly Diagnosed AML: Gemtuzumab Ozogamicin

The treatment, which was approved nearly 2 decades ago but withdrawn due to safety and efficacy concerns, now has a new indication.

September 1st 2017

5 Significant Developments With CAR-T Therapy

Surabhi Dangi-Garimella, PhD

A look at some of the major developments in the chimeric antigen receptor T (CAR-T) cell space.

August 25th 2017

Case Study Identifies New Trigger for CAR-T Cell Expansion in DLBCL in JCAR017 Trial

Surabhi Dangi-Garimella, PhD

Chimeric antigen receptor (CAR)-T cells can re-expand in a lymphoma patient months after the initial infusion and can also be active against the patient’s cancer, according to a new study.

August 24th 2017

Study Finds HPV Vaccination Underutilized by Childhood Cancer Survivors

Surabhi Dangi-Garimella, PhD

A new study in the Journal of Clinical Oncology identifies an increased role for physicians in boosting human papillomavirus (HPV) vaccination rates among childhood cancer survivors to reduce their risk of a second cancer.

August 21st 2017

FDA Approves Besponsa for Relapsed/Refractory Acute Lymphoblastic Leukemia

Alison Rodriguez

The FDA has approved Besponsa (inotuzumab ozogamicin) for treating adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

August 14th 2017

Matching PROs With Medical Records to Assess Comorbidities in Prostate Cancer

Surabhi Dangi-Garimella, PhD

Patient reported data can be a reliable source of information to ascertain comorbidities in patients with prostate cancer, says JAMA Oncology study.

August 9th 2017

Results of Phase 2 Study Investigating Luspatercept in MDS

Alison Rodriguez

The results of a phase 2 study that explored the effects of luspatercept in patients with lower-risk myelodysplastic syndromes (MDS) were presented at the 22nd Congress of the European Hematology Association by Acceleron Pharma Inc. The company is developing the drug with Celgene.

August 4th 2017

5 Developments With Cancer Immunotherapy

Surabhi Dangi-Garimella, PhD

There’s a lot happening in clinical practice with immunotherapy treatments: expanded indications for nivolumab and ipilimumab, biomarkers to judge patient response to combinations, and developments with CAR-T.

August 1st 2017

Enasidenib Approved for IDH2-Mutated Patients With Relapsed/Refractory AML

Surabhi Dangi-Garimella, PhD

Enasidenib (Idhifa), developed by Celgene and Agios, has been granted FDA approval in tandem with a companion diagnostic test to detect IDH-2 mutations.

July 28th 2017

Breakthrough Therapy Designation for Venetoclax in AML

Venetoclax (Venclexta), in combination with low dose cytarabine, has been granted a breakthrough therapy designation for use in elderly, treatment-naive patients with acute myeloid leukemia (AML) who cannot handle intensive chemotherapy.

July 24th 2017

Kite's CAR-T Therapy Produces Durable Remission in DLBCL, Study Finds

Christina Mattina

A study on long-term remission of diffuse large B-cell lymphoma (DLBCL) shows that Kite Pharma’s anti-CD19 chimeric antigen receptor-T (CAR-T) cell treatment resulted in remission for up to 56 months.

July 17th 2017

Daratumumab-Based Combination Effective in Relapsed/Refractory Multiple Myeloma, Short PFS in Heavily Pretreated Patients

Surabhi Dangi-Garimella, PhD

Managing heavily pretreated, often less fit, patients with relapsed/refractory multiple myeloma is a challenge in routine practice, as illustrated by the fact progression-free survival remains short, although daratumumab-based combination therapies are proven effective, according to results presented during a poster session at the 2017 American Society of Clinical Oncology Annual Meeting.

July 17th 2017

Phase 1 Study Results at ASCO Support First-Line Use of Daratumumab in Multiple Myeloma

Surabhi Dangi-Garimella, PhD

A phase 1 study, presented at the 2017 Annual Meeting of the American Society of Clinical Oncology, found that using daratumumab, an antibody that binds and inhibits the CD38 receptor, can improve patient response to treatment.

July 17th 2017

Daratumumab With Standard Regimen Improves PFS, ORR Independent of Cytogenetic Risk in Multiple Myeloma

Surabhi Dangi-Garimella, PhD

Updated trial results at the 2017 Annual Meeting of the American Society of Clinical Oncology showed the combinations of daratumumab with either lenalidomide and dexamethasone or bortezomib and dexamethasone prolonged progression-free survival for patients with relapsed refractory multiple myeloma.

July 12th 2017

CHESS Study Investigates Economic Burden of Severe Hemophilia in Europe

Alison Rodriguez

Severe hemophilia often results in a significant economic and psychological burden on patients, caregivers, and the healthcare system as a whole, according to recent research from Europe.

July 9th 2017

New Antibody Demonstrates 2-Pronged Approach in Treating Blood Cancer

Alison Rodriguez

A study published by BloodAdvances, a Journal of the American Society of Hematology, demonstrated the potential of the 2-pronged approach in treating non-Hodgkin lymphoma, multiple myeloma, and acute myeloid leukemia.

July 7th 2017

Phase 2 Trial Results Suggest Luspatercept Is Effective in Treating Myelodysplastic Syndrome

Alison Rodriguez

Treating myelodysplastic syndrome patients with luspatercept can increase hemoglobin and decrease the burden of red blood cell transfusion for more than 26 months, according to new results from a phase 2 trial.

June 29th 2017

Novel Antibody May Restore Immune Response to Rituximab for CLL

Christina Mattina

Among a group of patients with chronic lymphocytic leukemia (CLL) who were previously unresponsive to rituximab, a new antibody could help enable the immune system to attack the cancer cells, according to a study in PLOS One.

...

18 19 20 21 22 23 24 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions